Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Metrics to compare | NXL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −2.6x | −0.5x | |
PEG Ratio | −0.10 | −0.07 | 0.00 | |
Price / Book | 1.7x | 3.9x | 2.6x | |
Price / LTM Sales | 51.1x | 2.7x | 3.3x | |
Upside (Analyst Target) | - | 47.3% | 46.6% | |
Fair Value Upside | Unlock | 8.1% | 6.4% | Unlock |